BIOMARIN PHARMACEUTICAL INC (1BMRN.MI) Stock Price, Forecast & Analysis
Europe - Euronext Milan - BIT:1BMRN - US09061G1013 - Common Stock
1BMRN.MI Key Statistics, Chart & Performance
The current stock price of 1BMRN.MI is 50.7 EUR.
1BMRN.MI Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ARGX.BR | ARGENX SE | 65.13 | 42.70B | ||
| 1AE.DE | ARGENX SE | 65.22 | 42.77B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 20.72B | ||
| ABVX.PA | ABIVAX SA | N/A | 7.71B | ||
| 2X1.DE | ABIVAX SA | N/A | 7.64B | ||
| GXE.DE | GALAPAGOS NV | N/A | 1.88B | ||
| GLPG.AS | GALAPAGOS NV | N/A | 1.87B | ||
| 5CV.DE | CUREVAC NV | 6.71 | 876.36M | ||
| NANO.PA | NANOBIOTIX | N/A | 856.31M | ||
| IVA.PA | INVENTIVA SA | N/A | 782.22M | ||
| 6IV.DE | INVENTIVA SA | N/A | 753.57M | ||
| PHIL.MI | PHILOGEN SPA | 20 | 666.67M |
Related stock screener links
About 1BMRN.MI
Company Profile
BioMarin Pharmaceutical, Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. The company is headquartered in San Rafael California, California and currently employs 3,040 full-time employees. The firm has eight commercial therapies and a clinical and preclinical pipeline. Its commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno-associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Its key clinical programs include Vosoritide, BMN 333, BMN 390, BMN 351, BMN 349, and INZ-701. Its late-stage enzyme replacement therapy, INZ-701, is being developed for the treatment of ENPP1 deficiency.
Company Info
BIOMARIN PHARMACEUTICAL INC
770 Lindaro Street
San Rafael California CALIFORNIA US
Employees: 3040
Phone: 14155066700
BIOMARIN PHARMACEUTICAL INC / 1BMRN.MI FAQ
Can you describe the business of BIOMARIN PHARMACEUTICAL INC?
BioMarin Pharmaceutical, Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. The company is headquartered in San Rafael California, California and currently employs 3,040 full-time employees. The firm has eight commercial therapies and a clinical and preclinical pipeline. Its commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno-associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Its key clinical programs include Vosoritide, BMN 333, BMN 390, BMN 351, BMN 349, and INZ-701. Its late-stage enzyme replacement therapy, INZ-701, is being developed for the treatment of ENPP1 deficiency.
What is the current price of 1BMRN stock?
The current stock price of 1BMRN.MI is 50.7 EUR. The price increased by 1.48% in the last trading session.
Does 1BMRN stock pay dividends?
1BMRN.MI does not pay a dividend.
What is the ChartMill rating of BIOMARIN PHARMACEUTICAL INC stock?
1BMRN.MI has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 7 out of 10.
What sector and industry does BIOMARIN PHARMACEUTICAL INC belong to?
BIOMARIN PHARMACEUTICAL INC (1BMRN.MI) operates in the Health Care sector and the Biotechnology industry.
Can you provide the ownership details for 1BMRN stock?
You can find the ownership structure of BIOMARIN PHARMACEUTICAL INC (1BMRN.MI) on the Ownership tab.
1BMRN.MI Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to 1BMRN.MI.
1BMRN.MI Fundamental Analysis
ChartMill assigns a fundamental rating of 7 / 10 to 1BMRN.MI. 1BMRN.MI has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company.
1BMRN.MI Financial Highlights
Over the last trailing twelve months 1BMRN.MI reported a non-GAAP Earnings per Share(EPS) of 2.28. The EPS increased by 52% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 16.82% | ||
| ROA | 6.83% | ||
| ROE | 8.59% | ||
| Debt/Equity | 0.1 |
1BMRN.MI Forecast & Estimates
32 analysts have analysed 1BMRN.MI and the average price target is 67.13 EUR. This implies a price increase of 32.4% is expected in the next year compared to the current price of 50.7.
For the next year, analysts expect an EPS growth of 35.7% and a revenue growth 12.48% for 1BMRN.MI